Dolutegravir for the treatment of HIV. (Q37989555)

26 August 2017

title

Dolutegravir for the treatment of HIV. (English)

1 reference

26 August 2017

0 references

1 reference

1

Christine Katlama

0 references

Robert L. Murphy

object named as

Robert Murphy

series ordinal

2

0 references

language of work or name

English

0 references

publication date

2 March 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

523-530

1 reference

Prevention of HIV-1 infection with early antiretroviral therapy

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Novel integrase inhibitors for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661713

10.1517/13543784.2012.661713

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference